Recombinant Human NKG2A/CD159a Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10511-NK

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10511-NK-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all NKG2A/CD159a Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human NKG2A/CD159a protein
MD Human IgG1
(Pro100-Lys330)		 IEGR Human NKG2A/CD159a
(Pro94-Leu233)
Accession # P26715.2
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

43 kDa

SDS-PAGE

55-65 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human CD94 His-tag (Catalog # 9270-CD) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human NKG2A/CD159a Fc Chimera (Catalog # 10511-NK) binds with an ED50 of 2-16 µg/mL.

Scientific Data Images for Recombinant Human NKG2A/CD159a Fc Chimera Protein, CF

Recombinant Human NKG2A/CD159a Fc Chimera Protein Binding Activity.

When Recombinant Human CD94 His-tag (9270-CD) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human NKG2A/CD159a Fc Chimera (Catalog # 10511-NK) binds with an ED50 of 2-16 µg/mL.

Recombinant Human NKG2A/CD159a Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Human NKG2A/CD159a Fc Chimera Protein (10511-NK) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-65 kDa and 110-130 kDa, respectively.

Formulation, Preparation and Storage

10511-NK
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: NKG2A/CD159a

Killer cell lectin like receptor C1 (KLRC1), also known as NKG2A/NKG2B type II integral membrane protein or NK cell receptor A, is a member of the C-type lectin family (1). The NKG2 family is comprised of three unique receptor isoforms, NKG2A, NKG2C and NKG2E, which regulate both inhibitory and activating signals and are attractive targets for immune-checkpoint inhibition (1-3). Mature human NKG2A consists of a cytoplasmic domain containing two immunoreceptor tyrosine based inhibitory motifs (ITIM), a helical type II transmembrane domain, and an extracellular domain (ECD) with a C-type lectin motif (4). Within the mature ECD, human NKG2A shares 41% and 45% amino acid sequence identity with mouse and rat NKG2A, respectively. NKG2A is an inhibitory member of the NKG2 family and is expressed on CD56high natural killer (NK) cells, natural killer T (NKT) cells and a subset of CD8+ alpha beta T cells. NKG2A forms a disulfide linked, dimeric complex with another C-type lectin, CD94 (KLRD1), and functions by binding with HLA-E, a non-classical MHC I molecule (1-4). The increased expression of NKG2A in tumor-infiltrating NK cells is also emerging as a contributor in determining the poor prognosis of hepatocellular, lung or other carcinomas and in some cases may be a predictive factor of tumor metastasis (5). NKG2A immune checkpoint blockade in combination with PD-1/PD-L1 blockade or therapeutic cancer vaccines may hold promise in the treatment or multiple myeloma (MM) and various other solid and blood tumors or may improve the clinical outcome of patients who have undergone allogeneic hematopoietic stem cell transplantation (5-9).

References

  1. Haanen, J. and Cerundolo, V. (2018) Cell. 175:1720.
  2. Ceelan, B.C. and Antonia, S.J. (2019) Antonia Nature Reviews Clinical Oncology 16:277.
  3. Montfoort, N. et al. (2018) Cell. 175:1744.
  4. Brooks, A. et al. (1997) J. Exp. Med. 185:795.
  5. Zaghi, E. et al. (2019) J Leukoc Biol. 105:1243.
  6. van Hall, T. et al. (2019) J Immunother Cancer. 7:263.
  7. André, P. et al. (2019) Cell. 175:1731.
  8. Mahaweni, N.M. et al. (2018) Front Immunol. 9:2848.
  9. Borst, L. et al. (2020) doi: 10.1158/1078-0432.CCR-19-2095.

Long Name

Natural Killer G2A

Alternate Names

CD159a, Klrc1, NKG2

Entrez Gene IDs

3821 (Human); 16641 (Mouse); 102121106 (Cynomolgus Monkey)

Gene Symbol

KLRC1

Additional NKG2A/CD159a Products

Product Documents for Recombinant Human NKG2A/CD159a Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human NKG2A/CD159a Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.